“…Although various risk factors may impact prognosis for HL, for instance, patient‐related risk factors that affect outcome of its treatment , prognosis is believed to have improved substantially with advances in therapy, such as chemotherapy , targeted agents such as rituximab , and immunotherapy . Furthermore, the renewed use of diagnostic methods such as computed tomography texture analysis provides prognostic information for HL . These dramatic changes in disease management have transformed HL from an incurable disease to a chronic one .…”